Study Identifies FOXO3, STAT3, and ZNF341 as Core Biomarkers Linking Alzheimer's Disease and HIV-Associated Neurocognitive Disorder

Researchers have identified a three-molecule biomarker panel consisting of FOXO3, STAT3, and ZNF341 that highlights shared cellular senescence pathways and offers a potential blood-based diagnostic framework for Alzheimer's disease and HIV-associated neurocognitive disorder.

A peer-reviewed study integrated transcriptomic profiles from multiple cohorts of Alzheimer's disease (AD) and HIV-associated neurocognitive disorder (HAND) brain and blood samples.

Machine learning models identified FOXO3 as the top cross-disease biomarker, achieving a diagnostic area under the curve (AUC) of 0.922 in the AD temporal cortex and 0.771 in the HAND frontal cortex.

The transcription factor STAT3 ranked first as an inflammatory mediator in the integrated HAND cohort with an AUC of 0.759, while ZNF341 demonstrated the strongest transcription-level association across both diseases (beta = 5.09 in AD; beta = 4.85 in HAND).

A non-invasive, blood-based two-gene panel combining FOXO3 and ZNF341 yielded an AUC of 0.764 in a cohort of 329 blood samples, approaching clinical utility thresholds.

Pathway analyses revealed significant enrichment in cellular survival and senescence regulators, including the PI3K-Akt and FoxO signaling pathways.

The study provides computational validation for the 'senescence hypothesis' in neurodegenerative disease progression, showing that shared senescent pathways underlie etiologically distinct forms of cognitive decline.

The identification of FOXO3's negative correlation with MAPT (R = -0.690) and positive correlation with APP (R = 0.558) mechanically bridges established pathological hallmarks of AD with transcriptomic aging networks.

A non-invasive, blood-based diagnostic panel could potentially lower the cost and barrier to early neurodegenerative disease detection if validated in larger prospective clinical trials.

The validation of FOXO3-associated networks and cellular senescence regulators reinforces therapeutic strategies centered around autophagy restoration, epigenetic reprogramming, and selective clearance of senescent cells.

Targeted neurodegeneration pipelines that focus on microtubule-associated protein tau (MAPT) may benefit from network biology insights mapping how regulatory hubs like FOXO3 affect downstream tau expression.

Prospective validation of the FOXO3-STAT3-ZNF341 panel in independent, longitudinal clinical cohorts to establish diagnostic baseline accuracy and sensitivity to early-stage cognitive decline.